Company Encyclopedia
View More
name
Tango Therapeutics
TNGX.US
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
1.945 T
TNGX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking98/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-51.65%E
    • Profit Margin-151.15%E
    • Gross Margin42.73%B
  • Growth ScoreB
    • Revenue YoY53.29%A
    • Net Profit YoY18.54%B
    • Total Assets YoY-40.37%E
    • Net Assets YoY-30.17%E
  • Cash ScoreB
    • Cash Flow Margin-66.16%D
    • OCF YoY53.29%A
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreB
    • Gearing Ratio23.84%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat

    Stifel Nicolaus analyst Laura Prendergast has initiated a Buy rating for Tango Therapeutics (TNGX), citing the strategic positioning of vopimetostat as a potential best-in-class PRMT5 inhibitor for second-line PDAC treatment. The anticipated Phase 3 trial in 2026 and potential approval by 2029, along with synergy potential with RVMD’s RAS(ON) inhibitors, support a promising outlook. The company's cash runway into 2028 and strategic approach in PDAC contribute to the positive assessment. B. Riley Securities also maintains a Buy rating with a $14.00 price target.

    Tip Ranks·
    US
    TNGX
    -2.73%
    Tip Ranks·
    US
    TNGX
    -2.73%

    Virtus Investment Advisers LLC Sells 38,979 Shares of Tango Therapeutics, Inc. $TNGX

    Virtus Investment Advisers LLC reduced its holdings in Tango Therapeutics, Inc. by 67.7% in Q2, selling 38,979 shares. The firm's remaining 18,620 shares were valued at $95,000. Other institutional investors adjusted their positions, with some increasing their holdings. Tango Therapeutics' stock opened at $10.92, with a market cap of $1.47 billion. Analysts have mixed ratings, with a moderate buy consensus and a price target of $12.50. Recent insider trading saw major shareholder Rock Ventures Iv L.P. Third sell 477,401 shares.

    Market Beat·
    US
    TNGX
    -2.73%
    US
    VRTS
    +1.72%
    Market Beat·
    US
    TNGX
    -2.73%
    US
    VRTS
    +1.72%

    Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

    BOSTON, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference ...

    GlobeNewswire·
    US
    TNGX
    -2.73%
    GlobeNewswire·
    US
    TNGX
    -2.73%

    Tango Therapeutics (TNGX): Assessing Valuation Following New Equity Offering and Shelf Registration Moves

    Tango Therapeutics (TNGX) has announced a $100 million equity offering and multiple shelf registrations, raising questions about its valuation. The stock has surged 12.7% in one day and 220.45% year-to-date, with a price-to-sales ratio of 20.3x, above industry averages. Investors are evaluating whether the current valuation reflects future growth or poses risks due to potential dilution and high multiples. The company's ability to convert pipeline prospects into revenue is crucial for sustaining its stock price.

    Simplywall·
    US
    TNGX
    -2.73%
    Simplywall·
    US
    TNGX
    -2.73%

    Tango Therapeutics shares are trading higher. The company announced it filed for a mixed shelf of up to $100 million.

    benzinga_article·
    US
    TNGX
    -2.73%
    benzinga_article·
    US
    TNGX
    -2.73%
    © 2025 Longbridge｜Disclaimer